|
| Press Releases |
|
 |
|
| Friday, May 7, 2021 |
|
|
아방스 클리니컬, 174억 달러 규모 시장 수요를 충족하는 유전 기술 임상 시험 서비스 확대 |
| 호주의 바이오테크 임상수탁기관(CRO) 선두주자이자 프로스트&설리번(Frost & Sullivan)이 수여하는 아시아-태평양 CRO 마켓 리더십 어워드(Asia-Pacific CRO Market Leadership Award)를 수상한 바 있는 아방스 클리니컬은 2023년까지 174억 달러 규모로 증가할 것으로 예상되는 글로벌 수요를 충족할 수 있도록 유전 기술 임상 시험 서비스를 확대해 왔다. more info >> |
|
|
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand |
| The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. more info >> |
|
| Friday, April 23, 2021 |
|
|
Avance Clinical社がOracle Health Sciences Connectで「Decentralized Trials - No Going Back」と題した講演に招待されました |
| オーストラリアを代表するバイオテクノロジー企業向けCROであり、フロスト＆サリバン社のアジア太平洋CROマーケット・リーダーシップ・アワードを受賞したアヴァンス・クリニカルは、オラクル・ヘルス・サイエンス・コネクト・カンファレンスに招待され、分散型臨床試験の未来について発表しました。 more info >> |
|
|
아방스 클리니컬, 오라클 헬스 사이언스 커넥트에 초청되어 "분산형 실험 - 이전으로 돌아갈 수 없는 획기적 발전" 발표 |
| 호주의 바이오테크 임상수탁기관(CRO)선두주자이자 프로스트&설리번(Frost & Sullivan)이 수여하는 아시아태평양 CRO 마켓 리더십 어워드(Asia-Pacific CRO Market Leadership Award)를 수상한 바 있는 아방스 클리니컬은 오라클 헬스 사이언스 커넥트 컨퍼런스에 초청받아 분산형 임상실험(decentralized clinical trials, DCT)의 미래에 대해 발표했다. more info >> |
|
| Thursday, April 22, 2021 |
|
|
Avance Clinical受邀發表“分散試驗–不再回頭” 適用於Oracle Health Sciences Connect |
| 澳大利亞領先的生物技術CRO和Frost＆Sullivan亞太CRO市場領導獎獲得者Avance Clinical已應邀在Oracle Health Sciences Connect會議上介紹了分散臨床試驗的未來。 more info >> |
|
|
Avance Clinical受邀发表“分散试验–不再回头” 适用于Oracle Health Sciences Connect |
| 澳大利亚领先的生物技术CRO和Frost＆Sullivan亚太CRO市场领导奖获得者Avance Clinical已应邀在Oracle Health Sciences Connect会议上介绍了分散临床试验的未来。 more info >> |
|
|
Avance Clinical Invited to Present "Decentralized Trials - No Going Back" for Oracle Health Sciences Connect |
| The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference. more info >> |
|
| Friday, March 12, 2021 |
|
|
Avance臨床客戶Atossa Therapeutics宣布了第一階段臨床研究的最終結果，該研究表明針對COVID-19研發的AT-301鼻噴霧劑的安全性和耐受性 |
澳大利亞領先的生物技術CRO和Frost＆Sullivan亞太CRO市場領導獎獲得者Avance Clinical祝賀Atossa Therapeutics宣布了他們為COVID-19開發的AT-301鼻噴霧劑的第一階段最終結果。
more info >> |
|
|
Avance临床客户Atossa Therapeutics宣布了第一阶段临床研究的最终结果，该研究表明针对COVID-19研发的AT-301鼻喷雾剂的安全性和耐受性 |
| more info >> |
|
|
Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19 |
| The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
OSL Lists State-Supervised Gold-Backed Stablecoin USDKG as Platform Expands Asia's Digital Asset Ecosystem
May 22, 2026 23:30: JST
|
|
|
OSL Lists State-Supervised Gold-Backed Stablecoin USDKG as Platform Expands Asia's Digital Asset Ecosystem
May 22, 2026 22:30 HKT/SGT
|
|
|
Six Factors to Consider When Opting for a Credit Line in Singapore
May 22, 2026 19:05 HKT/SGT
|
|
|
Patents Build Solid Barriers, Technologies Achieve All-Round Breakthroughs, New Vision Leads the New Track of AR Interaction
May 22, 2026 18:46: JST
|
|
|
Patents Build Solid Barriers, Technologies Achieve All-Round Breakthroughs, New Vision Leads the New Track of AR Interaction
May 22, 2026 17:46 HKT/SGT
|
|
|
天辰生物通過聆訊：深耕過敏與自身免疫領域 臨床療效全面領先
May 22, 2026 16:32 HKT/SGT
|
|
|
天辰生物通过聆讯：深耕过敏与自身免疫领域 临床疗效全面领先
May 22, 2026 16:32 HKT/SGT
|
|
|
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
May 22, 2026 11:05: JST
|
|
|
雲頂新耀獲主要股東康橋資本增持 全球化佈局有望持續受益
May 22, 2026 10:59 HKT/SGT
|
|
|
GTJAI Won Two Awards at HR Asia 2026
May 22, 2026 10:49 HKT/SGT
|
|
|
國泰君安國際斬獲HR Asia 2026年度兩項大獎
May 22, 2026 10:49 HKT/SGT
|
|
|
国泰君安国际斩获HR Asia 2026年度两项大奖
May 22, 2026 10:49 HKT/SGT
|
|
|
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
May 22, 2026 10:05 HKT/SGT
|
|
|
云顶新耀获主要股东康桥资本增持 全球化布局有望持续受益
May 22, 2026 10:05 HKT/SGT
|
|
|
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 0:23 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
